Novartis Champions Cosentyx With More Long-Term Psoriasis Data
Executive Summary
Although its focus may be shifting somewhat towards other indications, the Swiss major has reported study read-outs that demonstrate the long-term efficacy of its IL-17A inhibitor blockbuster in nail and palmoplantar psoriasis.
You may also be interested in...
Novartis' Cosentyx Goes Head-To-Head With Humira
With the initiation of EXCEED and SURPASS, Novartis is aiming to challenge Humira’s status as the preferred first-line biologic for ankylosing spondylitis and psoriatic arthritis.
Novartis' Cosentyx Goes Head-To-Head With Humira
With the initiation of EXCEED and SURPASS, Novartis is aiming to challenge Humira’s status as the preferred first-line biologic for ankylosing spondylitis and psoriatic arthritis.
Revamped Novartis In Good Shape At 3Q Ahead Of CEO Succession
Novartis beat third-quarter forecasts, flagged its strengthening drug portfolio, and said its CEO transition remains on track for February 2018, but a decision on its eye care division awaits.